Exploring novel nucleic acid therapeutic delivery methods and therapeutic strategies
Exploring novel nucleic acid therapeutic delivery methods and therapeutic strategies
批准号:
10514270
负责人:
PETER SARNOW
金额:
$481.08万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-16 至 2025-04-30
关键词:
2019-nCoVAcuteAdultAdvanced DevelopmentAnimal ModelAnimalsAntiviral AgentsAreaBase SequenceBindingBiochemicalCell Culture TechniquesCell modelCellsChemicalsChemistryChimera organismClinicalCold ChainsCollaborationsCoronavirusCustomDataDevelopmentDevicesDisease modelDoseDrug Delivery SystemsDrug StabilityEnsureEnterovirus 71EvaluationFamily PicornaviridaeGene ExpressionGenesGeneticGenetic TranscriptionGenomeGoalsGuide RNAHamstersHepatitis C virusHumanImmunologyIn VitroInterdisciplinary StudyInternal Ribosome Entry SiteLibrariesLipidsLungMediatingMembrane ProteinsMessenger RNAMethodsModificationMusNebulizerNucleic AcidsOutcomeOutpatientsPancreatic ribonucleasePatternPeptidesPeptoidsPharmaceutical PreparationsProcessProdrugsProtease InhibitorProteinsRNARNA BindingRNA VirusesRNA vaccineRegulatory ElementReportingResearch PersonnelResistanceRibonucleasesRoleSARS-CoV-2 infectionSiteStructureSystemTechnologyTestingTherapeuticTranscriptTranslatingTranslationsTropismVariantVesicleViralViral Envelope ProteinsViral GenesViral GenomeViral ProteinsVirulenceVirusWorkbasebiological systemsbiophysical techniquescell typecircular RNAclinically relevantdesignemerging pathogenextracellular vesicleshealingimprovedin vivoinnovationlipid nanoparticlelocked nucleic acidlung basal segmentmRNA deliverymicrovesiclesmolecular recognitionnanoparticlenanoparticle deliverynext generationnovelnovel therapeutic interventionnucleic acid deliverynucleic acid-based therapeuticsnucleoside analogpandemic diseasepathogenpathogenic viruspreclinical studyrecruitscreeningsmall moleculestructural biologytargeted treatmenttherapeutic developmentviral RNAviral resistancevirology
中文摘要
摘要
该项目的总体目标是使用一个综合的,多学科的研究奋进,
在不同领域具有专业知识的研究人员一起推动新靶点的开发,
战略和交付方法,以治疗大流行病的病毒病原体,如SARS-CoV-2和
肠病毒71。中心假设是,病毒学、化学、
病毒RNA结构和动力学以及治疗传递将揭示病毒基因组中的新病毒愈合。
新型结构靶标在线性病毒RNA和最近发现的病毒基因组衍生的环状结构中的作用
将使用靶向RNA中不同结构的新型小分子来研究RNA。行动方式
的RNA靶向小分子将使用核糖核酸酶靶向嵌合体或RIBOTAC来扩展,
破坏目标RNA。合成的mRNA编码的Cas 13的组合,其是可活化的核糖核酸酶
(RNase)和指导RNA,结合基于雾化器的肺部递送,将使我们能够控制
这是因为它不依赖于内源性RNA酶。基于核酸的治疗剂可以是
用于调节任何所需的基因。然而,核酸必须进入细胞,这需要药物
输送系统。在这里,我们将使用两种互补的递送系统:(i)微泡介导的递送。
ARRDC 1介导的微囊泡(ARRDC 1-mediated microvesicles,ARRDC 1)是一种很有前途的药物递送系统,
分子可以同时和可重复地包装,提供了使用ARP 4同时
递送可靶向多种病毒种类或变体的多种核酸货物。因此,ARPNET提供了一个
用于包装和递送抗病毒RNA创新方法。(ii)下一代脂质纳米颗粒(LNP),
与基于雾化器的肺递送结合。我们将通过以下方式改善LNP介导的核酸递送:
改变LNP的组成,以确保LNP与临床相关,我们将只进行化学测试
简单、可生物降解、可扩展和立体纯的脂质。LNP-mRNA的巨大临床影响
疫苗和其他LNP-RNA药物强调了对下一代LNP的迫切需求,
治疗窗口或对新细胞类型的向性。为了实现这些目标,项目2将与
流行病援助核心结构生物学核心和翻译加速器核心。此外,这
该项目是项目1(LNA)、项目3(肽、类肽和
靶向病毒包膜和表面蛋白的降解剂),项目4(降解病毒蛋白的PROTAC),
项目5(蛋白酶抑制剂)和项目6(核苷类似物)。我们严格的,
经过验证的数据将使我们能够执行我们的目标,以确定新的目标,采用新的治疗方法,
战略,并应用抗SARS-CoV-2,EV-71和其他病毒的抗病毒药物的新传递系统,
大流行病的病原体
英文摘要
ABSTRACT
The overall objective of this project is to use an integrated, multidisciplinary research endeavor that brings
together investigators with expertise in diverse areas to advance the development of novel targets, therapeutic
strategies, and delivery methods to treat viral pathogens of pandemic concerns, such as SARS-CoV-2 and
enterovirus 71. The central hypothesis is that a combination of interdisciplinary expertise in virology, chemistry,
viral RNA structure and dynamics and therapeutic delivery will reveal novel Achille’s heals in viral genomes.
Roles for novel structural targets in linear viral RNA and in recently discovered viral genome-derived circular
RNAs will be studied, using novel small molecules that target distinct structures in RNAs. The mode of actions
of RNA-targeting small molecules will be extended using ribonuclease targeting chimeras, or RIBOTACs, that
destroy target RNAs. A combination of synthetic mRNA-encoded Cas13, which is an activable ribonuclease
(RNase), and guide RNAs, in conjunction with nebulizer-based lung delivery will enable us to control the amount
of the RNase available, as it is not reliant on endogenous RNases. Nucleic acid-based therapeutics can be
used to modulate any desired gene. However, the nucleic acid must enter the cell, which requires a drug
delivery system. Here, we will use two complementary delivery systems: (i) Microvesicle-mediated delivery.
ARRDC1-mediated microvesicles (ARMMs) are a promising drug delivery system, where multiple cargo
molecules can be packaged concurrently and reproducibly, offering the potential to use ARMMs to concurrently
deliver multiple nucleic acid cargos that can target multiple viral species or variants. Thus, ARMMs offer an
innovative method for packaging and delivery of antiviral RNAs. (ii) Next-generation lipid nanoparticles (LNPs),
in conjunction with nebulizer-based lung delivery. We will improve LNP-mediated nucleic acid delivery by
changing the LNP composition to ensure that the LNPs are clinically relevant, and we will only test chemically
simple, biodegradable, scalable, and stereopure lipids. The tremendous clinical impact of the LNP-mRNA
vaccines and other LNP-RNA drugs underscores the acute need for next-generation LNPs with improved
therapeutic windows or tropism to new cell types. To achieve these goals, Project 2 will interact with the
Pandemic Assistance Core Structural Biology Core and the Translation Accelerator Core. Further, this
project forms key bridge for the delivery of therapeutics in Project 1 (LNAs), Project 3 (peptides, peptoids, and
degraders that target viral envelopes and surface proteins), Project 4 (PROTACs that degrade viral proteins),
Project 5 (protease inhibitors), and Project 6 (nucleoside analogs). The expected outcomes from our rigorous,
validated data will enable the execution of our aims to identify novel targets, to employ novel therapeutic
strategies, and to apply novel delivery systems of antivirals against SARS-CoV-2, EV-71, and other viral
pathogens of pandemic concern.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Roles for hepatitis C virus-derived circular RNAs in infected cells
-
批准号:10442607
-
项目类别:
-
资助金额:$19.68万
-
财政年份:2021
-
负责人:PETER SARNOW
-
依托单位:
Roles for hepatitis C virus-derived circular RNAs in infected cells
-
批准号:10309048
-
项目类别:
-
资助金额:$23.62万
-
财政年份:2021
-
负责人:PETER SARNOW
-
依托单位:
Roles for RCK/DDX6 in hepatitis C virus pathogenesis and hepatocellular carcinoma
-
批准号:7698228
-
项目类别:
-
资助金额:$29.58万
-
财政年份:2009
-
负责人:PETER SARNOW
-
依托单位:
ANALYSIS OF VIRAL TRANSLATION COMPLEXES
-
批准号:7299499
-
项目类别:
-
资助金额:$11.6万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:8417691
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 and circular RNAs in flavivirus RNA amplification
-
批准号:9912689
-
项目类别:
-
资助金额:$54.95万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:8206508
-
项目类别:
-
资助金额:$39.15万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 and circular RNAs in flavivirus RNA amplification
-
批准号:10394245
-
项目类别:
-
资助金额:$54.95万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:8040024
-
项目类别:
-
资助金额:$39.09万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:7763187
-
项目类别:
-
资助金额:$29.35万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:8604665
-
项目类别:
-
资助金额:$39.26万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:7080546
-
项目类别:
-
资助金额:$30.91万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:8789347
-
项目类别:
-
资助金额:$39.32万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:7570062
-
项目类别:
-
资助金额:$29.6万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:7184292
-
项目类别:
-
资助金额:$30.06万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:7340763
-
项目类别:
-
资助金额:$29.54万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Translational control by microRNAs
-
批准号:6899224
-
项目类别:
-
资助金额:$27.52万
-
财政年份:2003
-
负责人:PETER SARNOW
-
依托单位:
Translational control by microRNAs
-
批准号:7086229
-
项目类别:
-
资助金额:$26.87万
-
财政年份:2003
-
负责人:PETER SARNOW
-
依托单位:
Translational control by microRNAs
-
批准号:6758526
-
项目类别:
-
资助金额:$27.52万
-
财政年份:2003
-
负责人:PETER SARNOW
-
依托单位:
Translational control by microRNAs
-
批准号:6689141
-
项目类别:
-
资助金额:$27.46万
-
财政年份:2003
-
负责人:PETER SARNOW
-
依托单位:
海外基金